Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$2.27 +10.7%	$1.44	$0.51 ▼ $2.86	$113.90M	-0.09	241,403 shs	194,027 shs
ESLA Estrella Immunopharma	$0.87	$0.91	$0.63 ▼ $1.78	$31.28M	0.34	18,464 shs	4,373 shs
OKYO OKYO Pharma	$2.96 -5.1%	$2.66	$0.85 ▼ $3.35	$117.35M	-0.09	209,075 shs	66,526 shs
TARA Protara Therapeutics	$3.07 -1.0%	$3.12	$1.60 ▼ $10.48	$119.60M	1.42	206,089 shs	161,319 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	-0.97%	+0.49%	+34.87%	+169.38%	+91.57%
ESLA Estrella Immunopharma	+7.17%	+6.48%	+0.24%	-14.38%	-37.00%
OKYO OKYO Pharma	-4.59%	0.00%	+11.03%	+118.18%	+213.57%
TARA Protara Therapeutics	-0.96%	-1.90%	+1.64%	-3.73%	+63.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNTB Connect Biopharma	3.1846 of 5 stars	3.8	3.0	3.8	2.5	0.0
ESLA Estrella Immunopharma	2.3735 of 5 stars	3.5	5.0	0.6	1.7	0.0
OKYO OKYO Pharma	2.8001 of 5 stars	3.5	5.0	2.0	1.7	0.0
TARA Protara Therapeutics	1.5865 of 5 stars	3.6	1.0	1.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTB Connect Biopharma	3.50	Strong Buy	$7.00	208.37% Upside
ESLA Estrella Immunopharma	3.00	Buy	$16.00	1,749.71% Upside
OKYO OKYO Pharma	3.00	Buy	$7.00	136.49% Upside
TARA Protara Therapeutics	3.17	Buy	$19.60	538.44% Upside

Current Analyst Ratings Breakdown

Latest ESLA, CNTB, TARA, and OKYO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	ESLA Estrella Immunopharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/22/2025	CNTB Connect Biopharma	Northland Capmk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/12/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$7.00
5/29/2025	ESLA Estrella Immunopharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/22/2025	TARA Protara Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$21.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTB Connect Biopharma	$26.03M	4.85	N/A	N/A	$1.67 per share	1.36
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	$0.12 per share	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.16) per share	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$4.77 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTB Connect Biopharma	-$15.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/5/2025 (Estimated)
ESLA Estrella Immunopharma	-$7.31M	-$0.26	N/A	∞	N/A	N/A	-1,132.38%	-273.91%	9/26/2025 (Estimated)
OKYO OKYO Pharma	-$4.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/12/2025 (Estimated)
TARA Protara Therapeutics	-$44.60M	-$1.72	N/A	N/A	N/A	N/A	-37.45%	-34.36%	8/12/2025 (Estimated)

Latest ESLA, CNTB, TARA, and OKYO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/5/2025	H1 2025	CNTB Connect Biopharma	-$0.22	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	TARA Protara Therapeutics	-$0.43	-$0.35	+$0.08	-$0.35	N/A	N/A
5/15/2025	Q1 2025	CNTB Connect Biopharma	-$0.26	-$0.19	+$0.07	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTB Connect Biopharma	0.01	10.25	10.25
ESLA Estrella Immunopharma	N/A	0.22	0.22
OKYO OKYO Pharma	N/A	0.40	0.40
TARA Protara Therapeutics	N/A	18.03	18.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTB Connect Biopharma	58.72%
ESLA Estrella Immunopharma	0.35%
OKYO OKYO Pharma	2.97%
TARA Protara Therapeutics	38.13%

Insider Ownership

Company	Insider Ownership
CNTB Connect Biopharma	22.60%
ESLA Estrella Immunopharma	55.10%
OKYO OKYO Pharma	40.46%
TARA Protara Therapeutics	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTB Connect Biopharma	110	55.56 million	43.00 million	Optionable
ESLA Estrella Immunopharma	N/A	36.17 million	16.24 million	Not Optionable
OKYO OKYO Pharma	7	37.61 million	22.39 million	Not Optionable
TARA Protara Therapeutics	30	38.58 million	33.76 million	Optionable

ESLA, CNTB, TARA, and OKYO Headlines

Recent News About These Companies

Protara Therapeutics (NASDAQ:TARA) Announces Quarterly Earnings Results

4 hours ago | marketbeat.com

Protara Therapeutics Reports Q2 2025 Financial Results

August 12 at 4:42 AM | msn.com

Protara Beats Q2 Loss Estimates

August 11 at 6:40 PM | aol.comA

Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

August 11 at 8:00 AM | globenewswire.com

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | gurufocus.com

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | globenewswire.com

Protara Therapeutics (TARA) to Release Quarterly Earnings on Tuesday

July 30, 2025 | marketbeat.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Consensus Recommendation of "Buy" from Brokerages

July 25, 2025 | marketbeat.com

Protara Therapeutics (NASDAQ:TARA) Shares Up 11% - Still a Buy?

July 22, 2025 | marketbeat.com

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - The Manila Times

July 2, 2025 | manilatimes.netM

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - Morningstar

July 2, 2025 | morningstar.comM

Protara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community - Nasdaq

July 2, 2025 | nasdaq.com

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

Protara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community

June 30, 2025 | quiverquant.comQ

Protara Therapeutics Announces Addition to the Russell 3000® Index

June 30, 2025 | globenewswire.com

Protara Therapeutics, Inc. (TARA) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

RAPT Therapeutics Appoints Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. to Board of Directors

June 23, 2025 | quiverquant.comQ

Protara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025

June 14, 2025 | seekingalpha.com

Chutes & Ladders—Protara gears up for next steps with commercial pro

June 7, 2025 | fiercebiotech.comF

The Escalator: Digitas Health, Bristol Myers Squibb, Inizio Evoke and more

June 4, 2025 | mmm-online.comM

Protara Therapeutics names new Chief Commercial Officer

June 4, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ESLA, CNTB, TARA, and OKYO Company Descriptions

Connect Biopharma NASDAQ:CNTB

$2.27 +0.22 (+10.73%)

Closing price 04:00 PM Eastern

Extended Trading

$2.38 +0.12 (+5.07%)

As of 07:12 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Estrella Immunopharma NASDAQ:ESLA

$0.86 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$0.88 +0.01 (+1.50%)

As of 05:58 PM Eastern

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

OKYO Pharma NASDAQ:OKYO

$2.96 -0.16 (-5.13%)

Closing price 03:59 PM Eastern

Extended Trading

$2.92 -0.04 (-1.35%)

As of 07:52 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Protara Therapeutics NASDAQ:TARA

$3.07 -0.03 (-0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$3.08 +0.01 (+0.33%)

As of 07:33 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time